Finally, on slide 24, our capital priorities remain unchanged. We have already returned $1.7 billion to shareholders in the first quarter of 2025 through dividends and share repurchases. And we will continue to pursue disciplined expense management and careful investment in the most promising pipeline opportunities both internally and externally. I'm also pleased to note that S&P recently upgraded Gilead Sciences, Inc.'s long-term debt rating from triple B plus with a positive outlook to A minus with a stable outlook. Recognizing the outlook for our HIV franchise and other products, combined with steady revenue growth and strong cash flow generation. Overall, Gilead Sciences, Inc. is on track to continue delivering demand-led volume growth a disciplined operating model, and strong cash flow that positions us well for the rest of 2025 and beyond. With that, I'll invite Rebecca to begin the Q&A.